Psychedelic-focused health company Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) recently made a string of announcements.
The company confirmed Dr. Roger McIntyre as its new CEO, a private placement raise of $10 million and the acquisition of a California-based ketamine treatment centre which marks the company’s expansion into the U.S.
Dr. Roger McIntyre: Champignon’s New CEO
McIntyre is a professor of psychiatry and pharmacology at the University of Toronto and head of the Mood Disorders Psychopharmacology Unit at Toronto’s University Health Network. He’s also executive director of the Brain and Cognition Discovery Foundation in Toronto and director for the Depression and Bipolar Support Alliance in Chicago, Illinois.
McIntyre told Benzinga his experience as head of an influential scientific research center in mood disorders, along with personal contact with mood disorder patients for over 20 years, provided him with the “clarion call” to achieve the goals that Champignon aspires for patients and investors.
"It’s a privileged opportunity to be named as Chief Executive Officer of …
Full story available on Benzinga.com